No Data
JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s (SHSE:600200) Low P/S No Reason For Excitement
February 27 A-share investment lightning rod︱Kunshan Kersen Science & Technology: the company does not produce AI glasses; JiangSu WuZhong Pharmaceutical Development: received a notice of case filing from the China Securities Regulatory Commission.
Marssenger Kitchenware shareholders HaiNing DaYou and HaiNing DaHong plan to collectively reduce their shareholding by no more than 2.94%; Dark Horse Technology Group major shareholder Wang QiFei plans to reduce his shareholding by no more than 2%; Cybrid Technologies Inc. shareholder YinHuang Investment plans to reduce its shareholding by no more than 3%; Shangsheng Electronics shareholder TongTai ChuangYe plans to reduce its shareholding by no more than 3.00%; Shenzhen Gongjin Electronics' Lidar products account for less than 1% of the company's revenue; Routon Electronic is not involved in the humanoid robot business; Kunshan Kersen Science & Technology does not produce AI glasses; JiangSu WuZhong Pharmaceutical Development has received a notice of case filing from the securities regulatory commission.
JiangSu WuZhong Pharmaceutical Development is suspected of violations related to information disclosure and has been filed for investigation after years of losses, just turning a profit.|Brief Announcement
① JiangSu WuZhong Pharmaceutical Development has been put under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws; ② The company has reported a net income loss for six consecutive years, yet aims to turn a profit in 2024 by focusing on a single product in the medical aesthetics sector; ③ Previously, the company faced several instances of being penalized for various legal violations, but none have occurred in the last three years.
Overview of the lifting of restrictions on trading A-shares | February 17.
According to the Zhitong Finance APP, on February 17, a total of 19 listed companies have unlocked their restricted shares, with a total market value of approximately 6.288 billion yuan. Today's specific situation of the unlocked restricted shares is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Share Number Luzhou Laojiao 000568 Stock-based Incentive 0.0371 million Jinling Pharmaceutical 000919 Stock-based Incentive 1.92 million Hubei Guangji Pharmaceutical 000952 Stock-based Incentive 2.5209 million JiangSu WuZhong Pharmaceutical Development 600200 Stock-based Incentive 0.9612 million China National Software & Service 600536 Stock-based Incentive 0.0572 million Shinva Medical Instrument 6005
Jiangsu Wuzhong: Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. 2024 Annual Results Pre-Profit Announcement
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. 2024 Annual Results Pre-Profit Announcement
Investors Aren't Buying JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s (SHSE:600200) Revenues